Cargando…
Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies
BACKGROUND: Cognitive impairment is a core feature of schizophrenia. While first- and second-generation antipsychotic drugs treat psychotic exacerbations, no treatment is approved for the cognitive dysfunction. We have identified ASP4345, a positive allosteric modulator of the dopamine type 1 (D(1))...
Autores principales: | Desai, Amit, Benner, Lauren, Wu, Ruishan, Gertsik, Lev, Uz, Tolga, Marek, Gerard J., Zhu, Tong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808976/ https://www.ncbi.nlm.nih.gov/pubmed/32533536 http://dx.doi.org/10.1007/s40262-020-00911-0 |
Ejemplares similares
-
Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D(1) receptor positive allosteric modulator in patients with schizophrenia
por: Desai, Amit, et al.
Publicado: (2020) -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)
por: Parmar, Deven V., et al.
Publicado: (2022) -
Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers
por: Chandorkar, Gurudatt, et al.
Publicado: (2017) -
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
por: Dawson, Rodney, et al.
Publicado: (2023) -
Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients
por: Duthaler, Urs, et al.
Publicado: (2016)